Decoy Therapeutics Inc. earnings releases DCOY

Annual Quarterly

Decoy Therapeutics Inc. last reported quarterly results on Jul 31, 2025, for Q2 FY2025 (the quarter ended Jun 30, 2025): diluted EPS of -$81.21. It usually reports 17–41 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 17–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Jul 31, 2025 31 days after quarter end	Q2 FY2025 ended Jun 30, 2025	—	-1 +32.8%	-81.21 -3326.6%
Jan 17, 2025 17 days after quarter end	Q4 FY2024 ended Dec 31, 2024	—	-1 -66.0%	-9.17 -411.8%
Aug 10, 2023 41 days after quarter end	— ended Jun 30, 2023	—	—	—
Nov 10, 2022 41 days after quarter end	— ended Sep 30, 2022	—	—	—
Aug 15, 2022 46 days after quarter end	— ended Jun 30, 2022	—	—	—
May 12, 2022 42 days after quarter end	— ended Mar 31, 2022	—	—	—
Mar 10, 2022 69 days after quarter end	— ended Dec 31, 2021	—	—	—
Aug 5, 2021 36 days after quarter end	— ended Jun 30, 2021	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: DCOY (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Houston, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1615219
Former names: Salarius Pharmaceuticals, Inc. (until Jan 9, 2026); Flex Pharma, Inc. (until Jul 22, 2019)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.